PharmacoEconomics - Open

2017 - 2025

Current editor(s): Timothy Wrightson and Christopher Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 7, issue 6, 2023

Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15 pp. 863-875

Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, James Mahon, Rachel Houten, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden and Pinki Munot

Characteristics and Quality Appraisal of the Economic Evaluations Done in Ethiopia: A Systematic Review pp. 877-886

Bereket Bahiru Tefera, Desalegn Getnet Demsie, Adane Yehualaw, Chernet Tafere, Kebede Feyisa, Malede Berihun Yismaw, Belayneh Kefale and Zewdu Yilma

Cost-Effectiveness of Non-pharmacological Interventions for Mild Cognitive Impairment and Dementia: A Systematic Review of Economic Evaluations and a Review of Reviews pp. 887-914

Gillian Eaglestone, Evdoxia Gkaintatzi, Harmony Jiang, Charlotte Stoner, Rosana Pacella and Paul McCrone

Trade-Offs between Vaccine Effectiveness and Vaccine Safety: Personal versus Policy Decisions pp. 915-926

Semra Ozdemir, Sean Ng, Vinh Anh Huynh, Axel Mühlbacher, Hiang Khoon Tan and Eric Andrew Finkelstein

Hospital Resource Utilization and Costs in Patients with Heart Failure in France pp. 927-940

Frank Chemouni, Tiffany Chihiro Nishikawa, Harinala Groyer, Oumou Diaby, Julien Chollet and Deborah Ittah

Retrospective Comparison of Survival Projections for CAR T-Cell Therapies in Large B-Cell Lymphoma pp. 941-950

Elisabeth F. P. Peterse, Elisabeth J. M. Verburg-Baltussen, Alexa Stewart, Fei Fei Liu, Christopher Parker, Maarten Treur, Bill Malcolm and Sven L. Klijn

Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data pp. 951-961

Luis Phillipe Nagem Lopes, Alexander Itria and Luciane Cruz Lopes

The EQ-5D-3L Valuation Study in Pakistan pp. 963-974

Madeeha Malik, Ning Yan Gu, Azhar Hussain, Bram Roudijk and Fredrick Dermawan Purba

Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States pp. 975-985

Ahmed Salem, Elizabeth M. La, Desmond Curran, Brandon J. Patterson, Justin Carrico, Stéphane Lorenc, Katherine A. Hicks, Sara Poston and Christopher F. Carpenter

Estimating Cumulative Health Care Costs of Childhood and Adolescence Autism Spectrum Disorder in Ontario, Canada: A Population-Based Incident Cohort Study pp. 987-995

Claire Oliveira and Bryan Tanner

Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada pp. 997-1006

Reka E. Pataky, Stirling Bryan, Mohsen Sadatsafavi, Stuart Peacock and Dean A. Regier

Model and Empirical Data-Based Cost-Utility Studies of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Protocol of a Systematic Review on Methodology and Quality pp. 1007-1013

L. A. Jong, X. Li, S. Emamipour, S. Werf, M. J. Postma, P. R. Dijk and T. L. Feenstra

Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15 pp. 1015-1015

Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, James Mahon, Rachel Houten, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden and Pinki Munot

Volume 7, issue 5, 2023

Cost Effectiveness of Different Platelet Preparation, Storage, Selection and Dosing Methods in Platelet Transfusion: A Systematic Review pp. 679-708

Jorien Laermans, Hans Van Remoortel, Hans Scheers, Bert Avau, Jørgen Georgsen, Susan Nahirniak, Nadine Shehata, Simon J. Stanworth, Emmy De Buck, Veerle Compernolle and Philippe Vandekerckhove

Humanistic and Economic Burden of IgA Nephropathy: Systematic Literature Reviews and Narrative Synthesis pp. 709-722

Kenar D. Jhaveri, Mark E. Bensink, Martin Bunke, Jonathon A. Briggs, David M. W. Cork and Anushya Jeyabalan

Health State Utility Values in Early-Stage Non-small Cell Lung Cancer: A Systematic Literature Review pp. 723-738

Nick Jovanoski, Seye Abogunrin, Danilo Maio, Rossela Belleli, Pollyanna Hudson, Sneha Bhadti and Libby G. Jones

Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England pp. 739-750

Tom Bromilow, Hayden Holmes, Laura Coote, Sam Woods and Joshua Pink

Healthcare Costs at the End of Life for Patients with Non-cancer Diseases and Cancer in Denmark pp. 751-764

Anne Høy Seemann Vestergaard, Lars Holger Ehlers, Mette Asbjoern Neergaard, Christian Fynbo Christiansen, Jan Brink Valentin and Søren Paaske Johnsen

Mapping the World Health Organization Disability Assessment Schedule (WHODAS 2.0) onto SF-6D Using Swedish General Population Data pp. 765-776

Anna Philipson, Lars Hagberg, Liselotte Hermansson, Jan Karlsson, Emma Ohlsson-Nevo and Linda Ryen

Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease pp. 777-792

Francis Shupo, Keith R. Abrams, Zanfina Ademi, Grace Wayi-Wayi, Natasa Zibelnik, Matt Kirchmann, Carolyn Rutherford and Kelly Makarounas-Kirchmann

Perceptions and Attitudes Regarding Medical Device Development in Canada Among Canadian Innovators: A Qualitative Study pp. 793-809

Ikennah L. Browne, Andrew J. Sutton and Wei Zhang

Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn’s Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases pp. 811-822

Chitra Karki, Dominick Latremouille-Viau, Inmaculada Gilaberte, Gary Hantsbarger, Hela Romdhani and Amy L. Lightner

Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT–Fatigue) in Patients with Crohn’s Disease and Ulcerative Colitis pp. 823-840

Edward V. Loftus, Ashwin N. Ananthakrishnan, Wan-Ju Lee, Yuri Sanchez Gonzalez, Kristina A Fitzgerald, Kori Wallace, Wen Zhou, Leighann Litcher-Kelly, Sarah B. Ollis, Sylvia Su and Silvio Danese

A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico pp. 841-849

Juan Carlos Garnica-Cuellar, Enrique Morales-Villegas, Carmen Alicia López-Forero, Bárbara Monroy-Cruz, Bhrugu Pariti, Swati Deshwal, Manisha Sekharan, Mariana Osorio-Hernández and Ida Caterina García-Appendini

Highly Purified Human Menopausal Gonadotropin (HP-hMG) Versus Recombinant Follicle-Stimulating Hormone (rFSH) for Controlled Ovarian Stimulation in US Predicted High-Responder Patients: A Cost-Comparison Analysis pp. 851-860

Andrew Khair, Tray Brown, Marie Markert, Carsten Rødseth Barsøe, Gaurang S. Daftary and Patrick W. Heiser

Correction: Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England pp. 861-861

Tom Bromilow, Hayden Holmes, Laura Coote, Sam Woods and Joshua Pink

Volume 7, issue 4, 2023

A Simple Cost-Effectiveness Model of Screening: An Open-Source Teaching and Research Tool Coded in R pp. 507-523

Yi-Shu Lin, James F O’Mahony and Joost Rosmalen

Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 525-536

Rebecca Bresnahan, Rachel Houten, Janette Greenhalgh, Sarah Nevitt, James Mahon, Sophie Beale, Angela Boland, Devarshi Bhattacharyya, Yenal Dundar, Joanne McEntee, Shreyans Gandhi, Nigel Fleeman and Marty Chaplin

Cost Effectiveness of Strategies for Caring for Critically Ill Patients with COVID-19 in Tanzania pp. 537-552

Hiral Anil Shah, Tim Baker, Carl Otto Schell, August Kuwawenaruwa, Khamis Awadh, Karima Khalid, Angela Kairu, Vincent Were, Edwine Barasa, Peter Baker and Lorna Guinness

Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries pp. 553-565

Mackenzie Mills and Panos Kanavos

Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland pp. 567-577

Esra Çakar, César Oniangue-Ndza, Ralph P. Schneider, Sven L. Klijn, Ursula M. Vogl, Christian Rothermundt and Jessica R. May

Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study pp. 579-591

Ryan Pulleyblank and Nikolaj Birk Larsen

Dealing with Time Estimates in Hospital Cost Accounting: Integrating Fuzzy Logic into Time-Driven Activity-Based Costing pp. 593-603

Fiona Koster, Marc R. Kok, Jaco Kooij, Geeke Waverijn, Angelique E. A. M. Weel-Koenders and Deirisa Lopes Barreto

Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective pp. 605-615

Cesarius Singgih Wahono, Laniyati Hamijoyo, Yuriawati Hendrawan, Liyana Rakinaturia, Neha Mittal, Prabal Khanna, Minal Jain and Harry Isbagio

Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis pp. 617-626

Julie Vanderpoel, Bruno Emond, Isabelle Ghelerter, Katherine Milbers, Marie-Hélène Lafeuille, Patrick Lefebvre and Lorie A. Ellis

Estimation of Health Utility Scores for Glycogen Storage Disease Type Ia pp. 627-638

Eliza Kruger, Daniel Aggio, Hayley Freitas and Andrew Lloyd

Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France pp. 639-653

Megane Caillon, Benoit Brethon, Chrissy Beurden-Tan, Romain Supiot, Antoine Mezo, Jean-Vannak Chauny, Istvan Majer and Arnaud Petit

Effect of Perioperative Oral Vitamin C Supplementation on In-Hospital Postoperative Medication Costs for Cardiac Surgery Patients: A Prospective, Single-Centre, Randomised Clinical Trial pp. 655-663

Jan Heerman, Charlotte Boydens, Silvie Allaert, Koen Cathenis, Koen Deryckere and Henk Vanoverschelde

Systematic Review and Cost-Consequence Analysis of Ambu aScope 5 Broncho Compared with Reusable Flexible Bronchoscopes: Insights from Two US University Hospitals and an Academic Institution pp. 665-678

Anders E. Kristensen, Jonathan S. Kurman, D. K. Hogarth, Sonali Sethi and Sabrina S. Sørensen

Volume 7, issue 3, 2023

Unmet Parenthood Goals, Health-Related Quality of Life and Apparent Irrationality: Understanding the Value of Treatments for Infertility pp. 337-344

Chris Skedgel, Patricia Cubi-Molla, David Mott, Sofia Gameiro, Jacky Boivin, Hareth Al-Janabi, John Brazier, Marie Markert, Fredrik L. Andersson and Mireia Jofre-Bonet

Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 345-358

Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik and Carlo Palmieri

Health Economic Studies of Surfactant Replacement Therapy in Neonates with Respiratory Distress Syndrome: A Systematic Literature Review pp. 359-371

Tiziana Magni, Chiara Ragni, Nicola Pelizzi, Sheetal Sharma, Lucia Perez-Kempner, Erika Turkstra, Jyothsna Nathani, Martina Orlovic and Natalia Meshchenkova

The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency pp. 373-381

Claudio Jommi and Carlotta Galeone

Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067 pp. 383-392

Taihang Shao, Mingye Zhao, Leyi Liang, Lizheng Shi and Wenxi Tang

Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States pp. 393-404

Aryana Sepassi, Ila M. Saunders, Mark Bounthavong, Randy A. Taplitz, Cathy Logan and Jonathan H. Watanabe

A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy pp. 405-416

Paolo Angelo Cortesi, Carla Fornari, Paolo Gisondi, Florenzo Iannone, Ippazio Cosimo Antonazzo, Elisabetta Aloisi, Martina Fiocchi, Daniela Ritrovato and Lorenzo Giovanni Mantovani

Economic Evaluation Comparing Virtual Reality with Child Life Programming for Non-sedated Pediatric Medical Imaging: A Cost-Consequence Analysis pp. 417-429

John Jacob, Chelsea Stunden, Dhayanand Deenadayalan and Luke Thomas

Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain pp. 431-441

A. M. Alonso Torres, A. G. Arévalo Bernabé, N. Becerril Ríos, M. F. Hellín Gil, J. M. Martínez Sesmero, V. Meca Lallana, Ll. Ramió-Torrentà, A. Rodríguez-Antigüedad, L. Gómez Maldonado, I. Triana Junco, M. Gómez-Barrera, N. Espinoza Cámac and I. Oyagüez

Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland pp. 443-454

Amy Dymond, Will Green, Mary Edwards, Maria Angeles Lopez Pont and Girish Gupta

Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer pp. 455-467

Andre Verhoek, Parneet Cheema, Barbara Melosky, Benoit Samson, Frances A. Shepherd, Filippo Marinis, Thomas John, Yi-Long Wu, Bart Heeg, Nadia Dalfsen, Benjamin Bracke, Miguel Miranda, Simon Shaw and Daniel Moldaver

Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) pp. 469-477

Owen Alan Edwards Cooper, Ola Ghatnekar, Natalia Piglowska, Charlie A. Smith, Paul Swinburn, James W. F. Catto, Günter Niegisch and Jørn Skibsted Jakobsen

Budget Impact of Three Improvement Targets for Compression Therapy for Patients with Deep Venous Thrombosis in The Netherlands pp. 479-491

Rachel H. P. Schreurs, Arina J. Cate-Hoek, Hugo Cate and Manuela A. Joore

Cost Analysis of a Transition Care Bundle Compared with Usual Care for COPD Patients Being Discharged from Hospital: Evaluation of a Randomized Controlled Trial pp. 493-505

Charles Yan, Jeff Round, Ilke Akpinar, Chantal E. Atwood, Lesly Deuchar, Mohit Bhutani, Richard Leigh and Michael K. Stickland

Volume 7, issue 2, 2023

The Impact of Digital Health Interventions for the Management of Type 2 Diabetes on Health and Social Care Utilisation and Costs: A Systematic Review pp. 163-173

Tiyi Morris, Fiona Aspinal, Jean Ledger, Keyi Li and Manuel Gomes

The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products pp. 175-187

Dawn Lee, Grant McCarthy, Omar Saeed, Rachel Allen, Kinga Malottki and Fleur Chandler

Estimating the Incidence-Based Cost of Illness Due to Hematopoietic Stem Cell Transplantation Using One-Year Insurance Claim Data in Korea pp. 189-197

Sol Kwon and Hye-Young Kang

A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada pp. 199-216

Anuja Chatterjee, Gijs Wetering, Ron Goeree, Carolyn Owen, Anne Marie Desbois, Stephane Barakat, Beenish S. Manzoor and Kavita Sail

Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods pp. 217-228

R. Brett McQueen, Nicholas D. Mendola, Ivett Jakab, Jeffrey Bennett, Kavita V. Nair, Bertalan Németh, András Inotai and Zoltán Kaló

Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal pp. 229-241

Paulo Martins, Björn Vandewalle, Jorge Félix, Carlos M. Capela, João J. Cerqueira, António V. Salgado, Diana G. Ferreira and Isabel Monteiro

A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States pp. 243-255

Rajiv Mallick, Rashad Carlton and Joris Stiphout

Attributable Patient Cost of Antimicrobial Resistance: A Prospective Parallel Cohort Study in Two Public Teaching Hospitals in Ghana pp. 257-271

Evans Otieku, Ama Pokuaa Fenny, Appiah-Korang Labi, Alex Owusu Ofori, Joergen Anders Lindholm Kurtzhals and Ulrika Enemark

Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China pp. 273-284

Shanlian Hu, Zhiliu Tang, James P. Harrison, Nadine Hertel, John R. Penrod, Jessica R. May, Ariadna Juarez-Garcia and Orban Holdgate

Cost-Utility Analysis of the Caresyntax Platform to Identify Patients at Risk of Surgical Site Infection Undergoing Colorectal Surgery pp. 285-298

Eoin Moloney, Atefeh Mashayekhi, Mehdi Javanbakht, Mohsen Rezaei Hemami and Michael Branagan-Harris

The Burden of Caring for Individuals with Tuberous Sclerosis Complex (TSC) Who Experience Epileptic Seizures: A Descriptive UK Survey pp. 299-312

Hanna Skrobanski, Kishan Vyas, Sally Bowditch, Lena Hubig, Edward Dziadulewicz, Louise Fish, Pooja Takhar and Siu Hing Lo

A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America pp. 313-320

Aaron Winn, Anirban Basu and Scott D. Ramsey

The Cost-Effectiveness of a Dance and Yoga Intervention for Girls with Functional Abdominal Pain Disorders pp. 321-335

Anna Philipson, Anna Duberg, Lars Hagberg, Sofie Högström, Lars Lindholm, Margareta Möller and Linda Ryen

Volume 7, issue 1, 2023

A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting pp. 3-36

Conor McCloskey, María Toboso Ortega, Sunita Nair, Maria João Garcia and Federico Manevy

Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial pp. 37-46

F. Felizzi, Aino Launonen and P.-O. Thuresson

Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial pp. 47-48

F. Felizzi, Aino Launonen and P.-O. Thuresson

Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia pp. 49-62

Karan K. Shah, Melina Willson, Blaise Agresta and Rachael L. Morton

Correction to: Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia pp. 63-63

Karan K. Shah, Melina Willson, Blaise Agresta and Rachael L. Morton

Estimating the Economic and Clinical Value of Introducing Ceftazidime/Avibactam into Antimicrobial Practice in Japan: A Dynamic Modelling Study pp. 65-76

Tetsuya Matsumoto, Akira Yuasa, Ryan Miller, Clive Pritchard, Takahisa Ohashi, Amer Taie and Jason Gordon

“Don’t Think Twice, It’s All Right”: Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in England pp. 77-91

Jiyeon Kang and John Cairns

Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis pp. 93-110

Mehdi Javanbakht, Jesse Fishman, Eoin Moloney, Peter Rydqvist and Amir Ansaripour

Healthcare Costs Before and After Diagnosis of Cancer of Unknown Primary Versus Ovarian Cancer in Australia pp. 111-120

Louisa G. Gordon, C. Wood, R. W. Tothill, P. M. Webb, P. Schofield and L. Mileshkin

Psychometric Validation of the Growth Hormone Deficiency–Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency–Parent Treatment Burden Measure (GHD-PTB) pp. 121-138

Meryl Brod, Michael Højby Rasmussen, Suzanne Alolga, Jane F. Beck, Donald M. Bushnell, Kai Wai Lee and Aristides Maniatis

Mapping of the World Health Organization Quality of Life Brief (WHOQOL-BREF) to the EQ-5D-5L in the General Thai Population pp. 139-148

Krittaphas Kangwanrattanakul

Mapping the Insomnia Severity Index Instrument to EQ-5D Health State Utilities: A United Kingdom Perspective pp. 149-161

François-Xavier Chalet, Teodora Bujaroska, Evi Germeni, Nizar Ghandri, Emilio T. Maddalena, Kushal Modi, Abisola Olopoenia, Jeffrey Thompson, Matteo Togninalli and Andrew H. Briggs